ПЕРСПЕКТИВНІ ПІДХОДИ У ПРОГНОЗУВАННІ ПЕРЕБІГУ РАКУ МОЛОЧНОЇ ЗАЛОЗИ ЗА НАДМІРНОЇ ВАГИ (огляд даних літератури та власних досліджень)
DOI:
https://doi.org/10.15407/oncology.2025.02.103Ключові слова:
рак молочної залози, ожиріння, співвідношення нейтрофілів до лімфоцитів, желатинази тромбоцитівАнотація
Авторами розглянуто, проаналізовано та підсумовано дані сучасної наукової літератури та результати власних досліджень щодо перспективних підходів у прогнозуванні перебігу раку молочної залози (РМЗ) за надмірної ваги. Зокрема, у статті розглядається роль біомаркерів крові, а саме співвідношення нейтрофілів до лімфоцитів, тромбоцитів та їх желатиназ, у прогнозуванні перебігу РМЗ при ожирінні. РМЗ є однією з найпоширеніших злоякісних пухлин у жінок, а його розвиток зумовлений як генетичними, так і модифікованими факторами ризику, серед яких особливу увагу приділено гормональним та репродуктивним аспектам за надмірної ваги пацієнток. Ожиріння розглядається, як один з факторів, що погіршує результати лікування РМЗ, особливо у жінок в постменопаузі. Зазначено, що надлишок жирової тканини сприяє розвитку прозапального стану, що впливає на агресивність пухлини. Особлива увага приділяється також ролі системного запалення, яке характеризується, зокрема, співвідношенням нейтрофілів до лімфоцитів, високі показники якого асоційовані з низькими показниками виживаності хворих на РМЗ, особливо у постменопаузі. Також розглядається роль тромбоцитів у прогнозуванні перебігу пухлини, зокрема через регуляцію ангіогенезу та метастазування.
Посилання
Obeagu EI, Babar Q, Vincent CC, et al. Therapeutic tar- gets in breast cancer signaling: a review. J Pharm Res Int 2021; 33: 82–99. https://doi.org/10.9734/JPRI/2021/v33 i56A33889
Aizaz M, Khan M, Khan FI, et al. Burden of breast cancer: developing countries perspective. Int J Innov Appl Res 2023; 11: 31–7. https://doi.org/10.58538/IJ
Ibekwe AM, Obeagu EI, Ibekwe CE, et al. Challenges of exclusive breastfeeding among working class women in a teaching hospital South East, Nigeria. J Pharm Res Int 2022; 34 (46A): 1–10. https://doi.org/10.9734/jpri/2022/ v34i46A36371
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017; 13: 1387–97. https:// doi.org/10.7150/ij s.21635
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317 (23): 2402– 12. https://doi.org/10.1001/jama.2017.7112
Britt K. Menarche, menopause, and breast cancer risk. Lan- cet Oncol 2012; 13 (11): 1071–2. https://doi.org/10.1016/ S1470-2045(12)70425-4
Sanchez-Covarrubias AP, Chery MJ, Barreto-Coehlo P, et al. Reproductive risk factor patterns in Caribbean wom- en with breast cancer across 4 generations. JAMA Netw Open 2024; 7 (10): e2438091. https://doi.org/10.1001/ jamanetworkopen.2024.38091
Obeagu EI, Obeagu GU. Breast cancer: a review of risk fac- tors and diagnosis. Medicine 2024; 103 (3): e36905. https:// doi.org/10.1097/MD.0000000000036905.
Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond) 2021; 41 (11): 1183–94. https://doi.org/10.1002/ cac2.12207
Park WK, Nam SJ, Kim SW, et al. The prognostic impact of HER2-low and menopausal status in triple-negative breast cancer. Cancers 2024; 16 (14): 2566. https://doi.org/ 10.3390/cancers15225361
Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 2025; 31 (4): 1154–62. https://doi. org/10.1038/s41591-025-03502-3
International Agency for Research on Cancer, World Health Organization. Estimated numbers of new cases and death from breast cancer from 2022 to 2050, Females, age [0–85+]. Available at: https://gco.iarc.who.int/tomorrow/ en/dataviz/trends?multiple_populations=1&cancers= 20&populations=903_904_905_908_909_935&group_ populations=1&types=0_1&sexes=2
World Atlas of Obesity 2024; World Obesity Federation: London, UK, 2024. Available at: https://www.worldobesity. org/resources/resource-library/world-obesity-atlas-2024
Janez A, Muzurovic E, Bogdanski P, et al. Modern manage- ment of cardiometabolic continuum: from overweight/ obesity to prediabetes/type 2 diabetes mellitus. Recommen- dations from the Eastern and Southern Europe Diabetes and Obesity Expert Group. Diabetes Ther 2024; 15: 1865–92. https://doi.org/10.1007/s13300-024-01615-5
Janić M, Janež A, El-Tanani M, Rizzo M. Obesity: recent advances and future perspectives. Biomedicines 2025; 13 (2): 368. https://doi.org/10.3390/biomedicines1302 0368
World Health Organization. Obesity. 2024. Available at: https://www.who.int/health-topics/obesity#tab=tab_1
García-Estévez L, González-Rodríguez M, Calvo I, et al. Obesity, overweight and breast cancer: new clinical data and implications for practice. Front Oncol 2025; 15: 1579876. https://doi.org/10.3389/fonc.2025.1579876
Garcia-Estevez L, Cortes J, Perez S, et al. Obesity and breast cancer: a paradoxical and controversial relationship influen- ced by menopausal status. Front Oncol 2021; 11: 705911. https://doi.org/10.3389/fonc.2021.705911
Engin A. Obesity-associated breast cancer: analysis of risk factors and current clinical evaluation. Adv Exp Med Biol 2024; 1460: 767–819. https://doi.org/10.1007/978-3-031- 63657-8_26
World Obesity Federation. World Obesity Atlas. 2023. Avail- able at: https://www.worldobesity.org/resources/resource- library/world-obesity-atlas-2023
Dehesh T, Fadaghi S, Seyedi M, et al. The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a system- atic review and meta-analysis. BMC Womens Health 2023; 23 (1): 392. https://doi.org/10.1186/s12905-023-02543-5
Ifeanyi E, Uzoma G. Breast cancer: a review of risk factors and diagnosis. Medicine 2024; 103 (3): e36905. https:// doi.org/10.1097/MD.0000000000036905
Schon SB, Cabre HE, Redman LM. The impact of obesity on reproductive health and metabolism in reproductive-age females. Fertil Steril 2024; 122 (2): 194–203. https://doi.
org/10.1016/j.fertnstert.2024.04.036
Tiainen S, Rilla K, Hämäläinen K, et al. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Breast Cancer Res Treat 2021; 185: 63–72. https://doi.org/10.1007/s10549-020- 05925-7
Heshmat-Ghahdarij K, Sarmadi V, Heidari A, et al. The neutrophil-to-lymphocyte ratio as a new prognostic fac- tor in cancers: a narrative review. Front Oncol 2023; 13: 1228076. https://doi.org/10.3389/fonc.2023.1228076
Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021; 122 (7): 474–88. https://doi.org/10.4149/BLL_2021_078
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neu- trophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 2022; 23 (7): 3636. https://doi.org/10.3390/ ij 3073636
Zhou Q, Dong J, Sun Q, et al. Role of neutrophil-to-lympho- cyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analy- sis. BMJ Open 2021; 11: e047957. https://doi.org/10.1136/ bmjopen-2020-047957
Ding N, Huang J, Li N, et al. Roles of neutrophil/lympho- cyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastu- zumab therapy. BMC Cancer 2020; 20: 235. https://doi. org/10.1186/s12885-020-06750-3
Bae SJ, Cha YJ, Yoon C, et al. Prognostic value of neutro- phil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neo- adjuvant chemotherapy. Sci Rep 2020; 10: 13078. https:// doi.org/10.1038/s41598-020-69965-1
Ijichi H, Tajiri W, Koi Y, et al. Preoperative neutrophil-to- lymphocyte ratio in postmenopausal breast cancer patients. J Surg Res 2024; 296: 98–105. https://doi.org/10.1016/j. jss.2023.11.075
Bubnovskaya LM, Samoylenko OA, Verbinenko AV, Ganu- sevich II. Tumor-associated adipocytes in the prognostic application of the preoperative ratio of neutrophils and lymphocytes in breast cancer. Problems and Achievements of Modern Biotechnology. Kharkiv, 2024: 170–1. https:// biotech.nuph.edu.ua/wp-content/uploads/2024/04/tezy_ iv_mizhnarodnoi_naukovo_praktychnoi_internet_konfer- entsii_problemy.pdf
Obeagu EI. Platelet activation in breast cancer: mechanisms and therapeutic opportunities — a narrative review. Ann Med Surg 2025; 87 (6): 3356–61. https://doi.org/10.1097/ MS9.0000000000003091
Anwar SL, Cahyono R, Avanti WS, et al. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: a retro- spective cohort study. Ann Med Surg 2021; 63: 102144. https://doi.org/10.1016/j.amsu.2021.01.092
Hurmuz P, Ozyigit G, Kilickap S, et al. Gemcitabine based trimodality treatment in patients with muscle invasive blad- der cancer: may neutrophil lymphocyte and platelet lym- phocyte ratios predict outcomes? Urol Oncol 2021; 39 (6): 368.e19–e29. https://doi.org/10.1016/j.urolonc.2020.11. 006
Wang Y, Tang Y, Gao X, et al. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and Ga-PSMA-PET-derived SUVmax values. Prostate 2022; 82 (15): 1415–21. https://doi.org/10.1002/pros. 24415
Wang L, Zhang K, Feng J, et al. The progress of platelets in breast cancer. Cancer Manag Res 2023; 15: 811–21. https:// doi.org/10.2147/CMAR.S418574
D’Ambrosi S, Nilsson RJ, Wurdinger T. Platelets and tumor- associated RNA transfer. Blood 2021; 137 (23): 3181–91. https://doi.org/10.1182/blood.2019003978
Miao S, Zhang Q, Chang W, Wang J. New insights into platelet-enriched miRNAs: production, functions, roles in tumors, and potential targets for tumor diagnosis and treatment. Mol Cancer Ther 2021; 20 (8): 1359–66. https:// doi.org/10.1158/1535-7163.MCT-21-0050
Best MG, Sol N, Vancura A, et al. Swarm intelligence- enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell 2017; 32 (2): 238–52. e9. https://doi.org/10.1016/j.ccell.2017.07.004
Karolczak K, Watala C. Blood platelets as an important but underrated circulating source of TGFβ. Int J Mol Sci 2021; 22 (9): 4492. https://doi.org/10.3390/ij 94492
Karsten MM, Beck MH, Rademacher A, et al. VEGF-A165b levels are reduced in breast cancer patients at primary di- agnosis but increase after completion of cancer treatment. Sci Rep 2020; 10 (1): 3635. https://doi.org/10.1038/s41598- 020-59823-5
Ward MP, Kane LE, Norris LA, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer 2021; 20 (1): 59. https://doi.org/ 10.1186/s12943-021-01347-1
Abdel-Hamid NM, Abass, et al. Matrix metalloproteinase contribution in management of cancer proliferation, metas- tasis and drug targeting. Mol Biol Rep 2021; 48: 6525–38. https://doi.org/10.1007/s11033-021-06635-z
Wu J, Heemskerk JW, Baaten CC. Platelet membrane recep- tor proteolysis: implications for platelet function. Front Cardiovasc Med 2021; 7: 608391.
Ganusevich II, Samoylenko OA, Verbinenko AV, Tropynina OS. Platelet gelatinases and survival of breast cancer patients with obesity: the relationship with menopausal status. Oncology 2024; 26 (2): 139–45. https://doi.org/10.15407/oncology. 2024.02.139 (in Ukrainian)
Ganusevich II, Virko SV, Riznichuk VO. Breast cancer in obesity: menopausal status and redox characteristics of adipose tissue dysfunction. Oncology 2023; 25 (2): 115–21. https://doi.org/10.15407/oncology.2023.02.115 (in Ukrai- nian)
Tropynina OS, Ganusevich II. Platelet gelatinase activ- ity in the course of breast cancer in obesity: dependence on menopausal status. From experimental and clinical pathophysiology to the achievements of modern medi- cine and pharmacy. Kharkiv, 2024: 209–10. https://pat. nuph.edu.ua/wp-content/uploads/2024/05/zbirnyk-konf- 16.05.24-1.pdf (in Ukrainian)
Ganusevich II, Samoylenko OA, Verbinenko AV, Tropyni- na OS. Redox state of blood and menopausal status of breast cancer patients with obesity. Abstracts of the Con- ference “Assessment of Quality of Life in Cancer Patients Covered in Experimental and Clinical Oncology Publica- tions: Challenges and Opportunities”, October 3–4, 2024, Kyiv, Ukraine. Exp Oncol 2024; 46 (4): 411. https://doi. org/10.15407/exp-oncology/2024.04.410
Abdul Rahman H, Zaim SNN, Suhaimei US, Jamain AA. Prognostic factors associated with breast cancer-specifi survival from 1995 to 2022: a systematic review and meta- analysis of 1,386,663 cases from 30 countries. Diseases 2024; 12 (6): 111. https://doi.org/10.3390/diseases12060111
Zhou Y, Yu S, Zhu L, et al. Molecular biomarkers for the prognosis of breast cancer: role of amino acid metabolism genes. J Physiol Biochem 2025. https://doi.org/10.1007/ s13105-025-01088-5
Gao W, Yao Y, Gao Q, et al. Impact of serum lipids on prog- nosis in breast cancer patients: a systematic review and meta-analysis. World J Surg Onc 2025; 23: 234. https:// doi.org/ 10.1186/s12957-025-03875-2
